Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Low-level viremia (LLV) after nucleos(t)ide analog treatment was presented as a possible cause of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). However, detailed information on patients’ adherence in the real world was lacking. This study aimed to evaluate the effects of LLV on HCC development, mortality, and cirrhotic complications among patients according to their adherence to entecavir (ETV) treatment. Methods: We performed a retrospective observational analysis of data from 894 consecutive adult patients with treatment-naïve CHB undergoing ETV treatment. LLV was defined according to either persistent or intermittent episodes of <2,000 IU/mL detectable hepatitis B virus DNA during the follow-up period. Good adherence to medication was defined as a cumulative adherence ≥90% per study period. Results: Without considering adherence in the entire cohort (n=894), multivariate analysis of the HCC incidence showed that LLV was an independent prognostic factor in addition to other traditional risk factors in the entire cohort (P=0.031). Good adherence group comprised 617 patients (69.0%). No significant difference was found between maintained virologic response and LLV groups in terms of the incidence of liver-related death or transplantation, HCC, and hepatic decompensation in good adherence group, according to multivariate analyses. Conclusions: In patients with treatment-naïve CHB and good adherence to ETV treatment in the real world, LLV during treatment is not a predictive factor for HCC and cirrhotic complications. It may be unnecessary to adjust their antiviral agent for patients with good adherence who experience LLV during ETV treatment.
Abstract
Background/Aims: Low-level viremia (LLV) after nucleos(t)ide analog treatment was presented as a possible cause of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). However, detailed information on patients’ adherence in the real world was lacking. This study aimed to evaluate the effects of LLV on HCC development, mortality, and cirrhotic complications among patients according to their adherence to entecavir (ETV) treatment. Methods: We performed a retrospective observational analysis of data from 894 consecutive adult patients with treatment-naïve CHB undergoing ETV treatment. LLV was defined according to either persistent or intermittent episodes of <2,000 IU/mL detectable hepatitis B virus DNA during the follow-up period. Good adherence to medication was defined as a cumulative adherence ≥90% per study period. Results: Without considering adherence in the entire cohort (n=894), multivariate analysis of the HCC incidence showed that LLV was an independent prognostic factor in addition to other traditional risk factors in the entire cohort (P=0.031). Good adherence group comprised 617 patients (69.0%). No significant difference was found between maintained virologic response and LLV groups in terms of the incidence of liver-related death or transplantation, HCC, and hepatic decompensation in good adherence group, according to multivariate analyses. Conclusions: In patients with treatment-naïve CHB and good adherence to ETV treatment in the real world, LLV during treatment is not a predictive factor for HCC and cirrhotic complications. It may be unnecessary to adjust their antiviral agent for patients with good adherence who experience LLV during ETV treatment.
참고문헌 (35)
- Grossi G, "Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)", Liver Int, 37(Suppl 1), pp.45~51 (2017)
- Zhang QQ, "Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications : a meta-analysis", Virol J, 8, pp.72~ (2011)
- Peng CY, "Hepatitis B virus-related decompensated liver cirrhosis : benefits of antiviral therapy", J Hepatol, 57, pp.442~450 (2012)
- Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
- Chang TT, "Long-term entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
- 이관식, "Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B", Clinical and Molecular Hepatology, 23(4), pp.331~339 (2017), 대한간학회[DOI]
- Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection", Hepatology, 58, pp.98~107 (2013)
- Arends P, "Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B : limited role for risk scores in Caucasians", Gut, 64, pp.1289~1295 (2015)
- Cho JY, "Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease", Gut, 63, pp.1943~1950 (2014)
- Lim YS, "Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine", Gastroenterology, 147, pp.152~161 (2014)
- David Sooik Kim, "Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir", Clinical and Molecular Hepatology, 25(3), pp.283~293 (2019), 대한간학회
- Sinn DH, "Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load", Hepatology, 62, pp.694~701 (2015)
- Kim JH, "Lowlevel viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment", Hepatology, 66, pp.335~343 (2017)
- Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
- Lee M, "Study of adherence comes to the treatment of chronic hepatitis B", J Hepatol, 54, pp.6~8 (2011)
- Vrijens B, "A new taxonomy for describing and defining adherence to medications", Br J Clin Pharmacol, 73, pp.691~705 (2012)
- Pawlotsky JM, "Virologic monitoring of hepatitis B virus therapy in clinical trials and practice : recommendations for a standardized approach", Gastroenterology, 134, pp.405~415 (2008)
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
- Shin JW, "Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir", Am J Gastroenterol, 113, pp.998~1008 (2018)
- Hong SP, "Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments", J Hepatol, 40, pp.837~844 (2004)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Chotiyaputta W, "Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B", J Hepatol, 54, pp.12~18 (2011)
- Papatheodoridis GV, "Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir", J Hepatol, 62, pp.363~370 (2015)
- Raffetti E, "Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B : a systematic review and meta-analysis", Liver Int, 36, pp.1239~1251 (2016)
- Eun JR, "Risk assessment for the development of hepatocellular carcinoma : according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virusrelated liver disease", J Hepatol, 53, pp.118~125 (2010)
- Park YH, "Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea", J Gastroenterol Hepatol, 29, pp.1005~1011 (2014)
- Abu-Amara M, "Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?", Semin Liver Dis, 33, pp.157~166 (2013)
- Lee SB, "Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area", Liver Int, 36, pp.1351~1361 (2016)
- Saitta C, "Hepatitis B virus(HBV)DNA integration in patients with occult HBV infection and hepatocellular carcinoma", Liver Int, 35, pp.2311~2317 (2015)
- Chotiyaputta W, "Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs", J Viral Hepat, 19, pp.205~212 (2012)
- Berg T, "Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection", Gastroenterology, 139, pp.1207~1217 (2010)
- Lieveld FI, "Patient adherence to antiviral treatment for chronic hepatitis B and C : a systematic review", Ann Hepatol, 12, pp.380~391 (2013)
- Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis", Hepatology, 58, pp.1537~1547 (2013)